Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study.
Benign prostatic hyperplasia
Ejaculation sparing
Lower urinary tract symptoms
Transperineal laser ablation of the prostate
Ultra-minimally invasive surgical techniques
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
received:
29
11
2023
accepted:
23
05
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
epublish
Résumé
Transperineal laser ablation (TPLA) is a new minimally-invasive surgical treatment for patients with benign prostatic obstruction (BPO). We report the perioperative and mid-term functional results of the first 100 consecutively patients undergoing TPLA at our institution. Clinical data from consecutive patients undergoing TPLA at our institution from April 2021 to July 2023 were prospectively collected. Primary endpoints were the postoperative changes in IPSS, QoL and MSHQ 3-item questionnaires and in Qmax and post-void residual volume (PVR). Overall, 100 consecutive patients underwent the procedure. Median age and prostate volume were 66 (IQR 60-75) years and 50 (IQR 40-70) ml, respectively. In the cohort, 14 (14%) patients had an indwelling catheter and 81 (81%) were under oral BPO therapy at the time of TPLA. Baseline median Qmax (ml/s) and PVR (ml) were 9.1 (IQR 6.9-12) and 90 (IQR 50-150), respectively, while median IPSS and QoL were 18 (IQR 15-23) and 4 (IQR 3-4). At all the follow-up timepoints, the evaluated outcomes on both symptoms and functional parameters showed a statistically significant improvement (p < 0.001). Antegrade ejaculation was preserved in all sexually active patients. No postoperative Clavien-Dindo > 2 complications were recorded. TPLA represents a safe option for selected well-informed patients swith LUTS due to BPO. Our prospective study confirms the feasibility and favorable perioperative and functional outcomes in a real-world cohort with heterogenous prostate volumes and patient characteristics.
Identifiants
pubmed: 38985193
doi: 10.1007/s00345-024-05077-z
pii: 10.1007/s00345-024-05077-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
402Informations de copyright
© 2024. The Author(s).
Références
Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA (2011) Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 29:179–184
doi: 10.1007/s00345-010-0605-8
pubmed: 20963421
Taub DA, Wei JT (2006) The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 7:272–281
doi: 10.1007/s11934-996-0006-0
pubmed: 16930498
Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TR, Mamoulakis C et al EAU Guidelines on Management of Non-neurogenic Male LUTS. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5
Elshal AM, Soltan M, El-Tabey NA, Laymon M, Nabeeh A (2020) Randomised trial of bipolar resection vs holmium laser enucleation vs Greenlight laser vapo-enucleation of the prostate for treatment of large benign prostate obstruction: 3-years outcomes. BJU Int 126:731–738
doi: 10.1111/bju.15161
pubmed: 32633020
Capogrosso P, Fallara G, Pozzi E, Schifano N, Candela L, Costa A et al (2022) Rates and predictors of postoperative complications after Holmium laser enucleation of the prostate (HoLEP) at a high-volume center. Minerva Urol Nephrol 74:461–466
doi: 10.23736/S2724-6051.21.04315-9
pubmed: 33887894
Qian X, Liu H, Xu D, Xu L, Huang F, He W et al (2017) Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and Meta-analysis. Aging Male 20:184–191
pubmed: 28368238
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C et al (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67:1066–1096
doi: 10.1016/j.eururo.2014.06.017
pubmed: 24972732
Yan J, Gao L, Xu G, Zhang J (2022) The effectiveness and safety of three surgical procedures for the treatment for benign prostatic hyperplasia: a network meta-analysis. Heliyon 8
Pan TT, Li SQ, Dai Y, Qi JX (2023) Observation of complications assessed by Clavien-Dindo classification in different endoscopic procedures of benign prostatic hyperplasia: an observational study. Med (Baltim) 102:E32691
doi: 10.1097/MD.0000000000032691
Behr A, Salleron J, Mazeaud C, Larose C, Dagry A, Balkau B et al (2023) Comparison of surgical procedures for benign prostatic hyperplasia of medium-volume prostates: evaluation of the causes of rehospitalization from the French National Hospital Database (PMSI-MCO). World J Urol 41:2481–2488
doi: 10.1007/s00345-023-04509-6
pubmed: 37550549
Nguyen DD, Li T, Ferreira R, Baker Berjaoui M, Nguyen AV, Chughtai B et al (2023) Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: a review of Aquablation, Rezum, and transperineal laser prostate ablation. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/S41391-023-00669-Z
doi: 10.1038/S41391-023-00669-Z
pubmed: 38114598
pmcid: 10638081
Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D, Group of the Young Academic Urologists Working Party of the European Association of Urology and of the Lower Tract and Research Group of the European Section of Uro-technology (2021) Uro-technology and SoMe Working. New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes. Eur Urol Open Sci. ;33:28–41. doi: 10.1016/j.euros.2021.08.009. PMID: 34604814; PMCID: PMC8473553
Sessa F, Polverino P, Siena G, Bisegna C, Lo Re M, Spatafora P et al (2023) Transperineal laser ablation of the prostate (TPLA) for lower urinary tract symptoms due to Benign Prostatic obstruction. J Clin Med 12(3):793. https://doi.org/10.3390/jcm12030793 PMID: 36769454; PMCID: PMC9918261
doi: 10.3390/jcm12030793
pubmed: 36769454
pmcid: 9918261
Tzelves L, Nagasubramanian S, Pinitas A, Juliebø-Jones P, Madaan S, Sienna G et al (2023) Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: a systematic review of existing literature. Ther Adv Urol 15:1–20
doi: 10.1177/17562872231198634
Sessa F, Bisegna C, Polverino P, Gacci M, Siena G, Cocci A et al Transperineal laser ablation of the prostate (TPLA) for selected patients with lower urinary tract symptoms due to benign prostatic obstruction: a step-by-step guide. Urol Video J, 15, 2022, 100167, ISSN 2590 – 0897, https://doi.org/10.1016/j.urolvj.2022.100167
Laganà A, Di Lascio G, Di Blasi A, Licari LC, Tufano A, Flammia RS et al (2023) Ultrasound – guided SoracteLite
doi: 10.1007/s00345-023-04322-1
pubmed: 36853444
pmcid: 10160153
Manenti G, Perretta T, Calcagni A, Ferrari D, Ryan CP, Fraioli F et al (2021) 3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia. Eur Radiol Exp 5
Pacella CM, Patelli G, Iapicca G, Manenti G, Perretta T, Ryan CP et al (2020) Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis 23:356–363
doi: 10.1038/s41391-019-0196-4
pubmed: 31827239
Frego N, Saita A, Casale P, Diana P, Contieri R, Avolio PP et al (2021) Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. World J Urol 39:3867–3873
doi: 10.1007/s00345-021-03685-7
pubmed: 33811512
Bertolo R, Iacovelli V, Cipriani C, Carilli M, Vittori M, Antonucci M et al (2023) Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: a randomized trial. BJU Int 132:100–108
doi: 10.1111/bju.16008
pubmed: 36917033
Sessa F, Polverino P, Bisegna C, Siena G, Lo Re M, Spatafora P et al (2022) Transperineal laser ablation of the prostate with EchoLaser™ system: perioperative and short-term functional and sexual outcomes. Front Urol 2:969208. https://doi.org/10.3389/fruro.2022.969208
doi: 10.3389/fruro.2022.969208
Campobasso D, Siena G, Chiodini P, Conti E, Franzoso F, Maruzzi D et al (2023) Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study. Prostate Cancer Prostatic Dis 26:410–414
doi: 10.1038/s41391-022-00587-6
pubmed: 36042295
Cindolo L, Morselli S, Campobasso D, Conti E, Sebastiani G, Franzoso F et al (2023) One-year outcomes after water vapor thermal therapy for symptomatic benign prostatic hyperplasia in an unselected Italian multicenter cohort. Minerva Urol Nephrol 75:203–209
doi: 10.23736/S2724-6051.22.05080-7
pubmed: 36656128
Reale G, Cimino S, Bruno G, Palmieri F, Giardina R, Russo GI et al (2019) Aquabeam® System’ for benign prostatic hyperplasia and LUTS: birth of a new era. A systematic review of functional and sexual outcome and adverse events of the technique. Int J Impot Res 31:392–399
doi: 10.1038/s41443-019-0158-3
pubmed: 31175340
Chughtai B, Thomas D (2018) Pooled Aquablation results for American men with lower urinary tract symptoms due to Benign Prostatic Hyperplasia in large prostates (60–150 cc). Adv Ther 35:832–838
doi: 10.1007/s12325-018-0722-0
pubmed: 29873008
Polverino P, Lo Re M, Saladino M, Pecoraro A, Moscardi L, Rivetti A et al Could transperineal interstitial laser ablation of the prostate be the right option for highly-comorbid patients with lower urinary tract symptoms due to benign prostatic obstruction? A preliminary single-center experience focusing on functional and safety outcomes. Minerva Urol. Nephrol.(accepted, publication ongoing)
Salvador Hidalgo D, Bernardello Ureta M, Sbriglio M, García Gámez A, Sampere Moragas J, Areal Calama J et al (2021) Prostatic artery embolization treatment for patients with benign prostatic hyperplasia who are permanent urinary catheter users ineligible for de-obstructive surgery. Actas Urol Esp 45:481–485
doi: 10.1016/j.acuro.2021.04.001
pubmed: 34326030
Young S, Moran P, Golzarian J (2022) Ejaculatory dysfunction following prostate artery embolization: a retrospective study utilizing the male sexual health questionnaire-ejaculation dysfunction questionnaire. Diagn Interv Imaging 103:310–315
doi: 10.1016/j.diii.2022.01.003
pubmed: 35086788
Manfredi C, Arcaniolo D, Spatafora P, Crocerossa F, Fusco F, Verze P et al (2022) Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol. ;74(4):389–399. https://doi.org/10.23736/S2724-6051.21.04530-4 . Epub 2021 Jul 26. PMID: 34308611
Cocci A, Bocchino AC, Cito G, Lisa A, Russo GI, Giudice AL et al (2021) Role of Rezum in the treatment of benign prostate hyperplasia: a review of the literature. Turkish J Urol 47:452–460
doi: 10.5152/tud.2021.21128